Meeting
2021 ASCO Annual Meeting
Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.
Authors
Chandtip Chandhasin
Tachyon Therapeutics, Houston, TX
Chandtip Chandhasin , Sanghee Yoo , Joselyn Del Rosario , Young K Chen , Jeffrey Stafford , Frank Perabo , Michael F. Clarke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3105)
DOI
10.1200/JCO.2021.39.15_suppl.3105
Abstract #
3105
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.
First Author: Margaret Lee
Poster
2018 ASCO Annual Meeting
COTI-2, a potent orally available small molecule targeting mutant p53, with promising efficacy as monotherapy and combination treatment in preclinical tumor models.
First Author: Richard T Ho
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The interaction of radiotherapy and dual inhibition of BET and HAT/p300 in colorectal cancer.
First Author: Michael Matthew Pennock
Poster
2023 ASCO Annual Meeting
TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.
First Author: Yelena Y. Janjigian